About acurx pharmaceuticals inc - ACXP
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.
ACXP At a Glance
Acurx Pharmaceuticals, Inc.
259 Liberty Avenue
New York, New York 10305
| Phone | 1-917-533-1469 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -7,966,538.00 | |
| Sector | Health Technology | Employees | 4 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ACXP Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.11 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.473 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
ACXP Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,991,634.50 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ACXP Liquidity
| Current Ratio | 3.176 |
| Quick Ratio | 3.176 |
| Cash Ratio | 3.121 |
ACXP Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -137.979 |
| Return on Equity | -270.80 |
| Return on Total Capital | -151.208 |
| Return on Invested Capital | -270.80 |
ACXP Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |